> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Interchangeable Biosimilar Bill Introduced
- URL: https://www.fdaweb.com/interchangeable-biosimilar-bill-introduced/
- Published: 2025-09-24T12:00:00.000Z
- Updated: 2026-09-14T15:22:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159931

Reps. **August Pfluger** (R-TX) and **Greg Landsman** (D-OH) have introduced the Biosimilar Red Tape Elimination Act, which they say would improve patient access to lower-cost prescription medication and increase competition in the biological drug market by automatically deeming biosimilar drugs as interchangeable with their branded counterparts upon FDA approval. A [statement](https://pfluger.house.gov/news/documentsingle.aspx?DocumentID=2588&ref=fdaweb.com) issued by Pfluger (contains a link to the bill text) says the measure would:

- strike the current requirement in the code that has been used to justify switching studies;
- create a cooldown period for certain biologics that were already granted exclusive interchangeable status; and
- instruct HHS and FDA to issue or retract relevant guidance.

Companion bipartisan legislation was introduced in the Senate earlier this year, the statement says.